Decrease in circulating DNA, IL-10 and BAFF levels in newly-diagnosed SLE patients after corticosteroid and chloroquine treatment

Cellular Immunology

Volumn 276, Issue 1-2, 2012, Pages 196-203

  Cepika, Alma Martina ^a,b,f   Soldo Jureša, Dragica ^c,g   Morović Vergles, Jadranka ^c   Malenica, Branko ^d   Šantak, Maja ^b   Kapitanović, Sanja ^e   Mayer, Miroslav ^d   Anić, Branimir ^d   Sentić, Mirna ^d   Gagro, Alenka ^a,b  

^a Croatia   (Croatia)

^b INSTITUTE OF IMMUNOLOGY   (Croatia)

^c University of Zagreb School of Medicine   (Croatia)

^d KBC Zagreb   (Croatia)

^e RUDER BO KOVI INSTITUTE   (Croatia)

^f BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^g University of Zagreb   (Croatia)

Author keywords

BAFF; Circulating DNA; CpG; IL 10; Systemic lupus erythematosus; TLR9

Indexed keywords

B CELL ACTIVATING FACTOR; CD86 ANTIGEN; CHLOROQUINE; DNA; INTERLEUKIN 10; METHYLPREDNISOLONE; TOLL LIKE RECEPTOR 9;

ADULT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADRENAL CORTEX HORMONES; ADULT; ANTIRHEUMATIC AGENTS; B-CELL ACTIVATING FACTOR; CELLS, CULTURED; CHLOROQUINE; DNA; FEMALE; HUMANS; INTERLEUKIN-10; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MONOCYTES;

MURINAE;

EID: 84863880382     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.05.009     Document Type: Article

References (75)

1. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N. Engl. J. Med. 2008, 358:929-939.
2. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2001, 2:764-766.
3. Kyttaris V.C., Juang Y.T., Tsokos G.C. Immune cells and cytokines in systemic lupus erythematosus: an update. Curr. Opin. Rheumatol. 2005, 17:518-522.
4. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003, 197:711-723.
5. Munoz L.E., van Bavel C., Franz S., Berden J., Herrmann M., van der Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008, 17:371-375.
6. Chen J.A., Meister S., Urbonaviciute V., Rodel F., Wilhelm S., Kalden J.R., et al. Sensitive detection of plasma/serum DNA in patients with systemic lupus erythematosus. Autoimmunity 2007, 40:307-310.
7. Raptis L., Menard H.A. Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J. Clin. Invest. 1980, 66:1391-1399.
8. Steinman C.R. Circulating DNA in systemic lupus erythematosus. Isolation and characterization. J. Clin. Invest. 1984, 73:832-841.
9. Bartoloni E., Ludovini V., Alunno A., Pistola L., Bistoni O., Crino L., et al. Increased levels of circulating DNA in patients with systemic autoimmune diseases: a possible marker of disease activity in Sjogren's syndrome. Lupus 2011, 20:928-935.
10. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.[see comment]. Nature 2002, 416:603-607.
11. Boule M.W., Broughton C., Mackay F., Akira S., Marshak-Rothstein A., Rifkin I.R. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 2004, 199:1631-1640.
12. Means T.K., Latz E., Hayashi F., Murali M.R., Golenbock D.T., Luster A.D. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 2005, 115:407-417.
13. Macfarlane D.E., Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J. Immunol. 1998, 160:1122-1131.
14. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69:20-28.
15. Costedoat-Chalumeau N., Leroux G., Piette J.C., Amoura Z. Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?. Joint Bone Spine 2010, 77:4-5.
16. Ben-Zvi I., Kivity S., Langevitz P., Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin. Rev. Allergy Immunol. 2011, Epub Jan 8.
17. Wardemann H., Yurasov S., Schaefer A., Young J.W., Meffre E., Nussenzweig M.C. Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377.
18. Yurasov S., Wardemann H., Hammersen J., Tsuiji M., Meffre E., Pascual V., et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 2005, 201:703-711.
19. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202.
20. Gantner F., Hermann P., Nakashima K., Matsukawa S., Sakai K., Bacon K.B. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides. Eur. J. Immunol. 2003, 33:1576-1585.
21. He B., Qiao X., Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J. Immunol. 2004, 173:4479-4491.
22. Vollmer J., Weeratna R.D., Jurk M., Samulowitz U., McCluskie M.J., Payette P., et al. Oligodeoxynucleotides lacking CpG dinucleotides mediate toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology 2004, 113:212-223.
23. Wagner M., Poeck H., Jahrsdoerfer B., Rothenfusser S., Prell D., Bohle B., et al. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J. Immunol. 2004, 172:954-963.
24. Beebe A.M., Cua D.J., De Waal Malefyt R. The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev. 2002, 13:403-412.
25. Chun H.Y., Chung J.W., Kim H.A., Yun J.M., Jeon J.Y., Ye Y.M., et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 2007, 27:461-466.
26. Houssiau F.A., Lefebvre C., Vanden Berghe M., Lambert M., Devogelaer J.P., Renauld J.C. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995, 4:393-395.
27. Chung E.Y., Liu J., Zhang Y., Ma X. Differential expression in lupus-associated IL-10 promoter single-nucleotide polymorphisms is mediated by poly (ADP-ribose) polymerase-1. Genes Immun. 2007, 8:577-589.
28. Ronnelid J., Tejde A., Mathsson L., Nilsson-Ekdahl K., Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann. Rheum. Dis. 2003, 62:37-42.
29. Ogden C.A., Pound J.D., Batth B.K., Owens S., Johannessen I., Wood K., et al. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J. Immunol. 2005, 174:3015-3023.
30. Nardelli B., Belvedere O., Roschke V., Moore P.A., Olsen H.S., Migone T.S., et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001, 97:198-204.
31. Lesley R., Xu Y., Kalled S.L., Hess D.M., Schwab S.R., Shu H.B., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
32. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
33. Groom J.R., Fletcher C.A., Walters S.N., Grey S.T., Watt S.V., Sweet M.J., et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med. 2007, 204:1959-1971.
34. Litinskiy M.B., Nardelli B., Hilbert D.M., He B., Schaffer A., Casali P., et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 2002, 3:822-829.
35. Becker-Merok A., Nikolaisen C., Nossent H.C. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006, 15:570-576.
36. Collins C., Gavin A., Migone T.S., Hilbert D., Nemazee D., Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res. Ther. 2005, 8:R6.
37. Ju S., Zhang D., Wang Y., Ni H., Kong X., Zhong R. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin. Biochem. 2006, 39:1131-1137.
38. Petri M., Stohl W., Chatham W., McCune W.J., Chevrier M., Ryel J., et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008, 58:2453-2459.
39. Stohl W., Metyas S., Tan S.M., Cheema G.S., Oamar B., Xu D., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003, 48:3475-3486.
40. Zhang J., Roschke V., Baker K.P., Wang Z., Alarcon G.S., Fessler B.J., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 2001, 166:6-10.
41. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992, 35:630-640.
42. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.[see comment]. Arthritis Rheum. 1997, 40:1725.
43. Webster J.I., Tonelli L., Sternberg E.M. Neuroendocrine regulation of immunity. Annu. Rev. Immunol. 2002, 20:125-163.
44. Agarwal S.K., Marshall G.D. Glucocorticoid-induced type 1/type 2 cytokine alterations in humans: a model for stress-related immune dysfunction. J. Interferon Cytokine Res. 1998, 18:1059-1068.
45. Cepika A.M., Gagro A., Bace A., Tjesic-Drinkovic D., Kelecic J., Baricic-Voskresensky T., et al. Expression of chemokine receptor CX3CR1 in infants with respiratory syncytial virus bronchiolitis. Pediatr. Allergy Immunol. 2008, 19:148-156.
46. Ivancic-Jelecki J., Brgles M., Santak M., Forcic D. Isolation of cell-free DNA from plasma by chromatography on short monolithic columns and quantification of non-apoptotic fragments by real-time polymerase chain reaction. J. Chromatogr. 2009, 1216:2717-2724.
47. Batzer M.A., Alegria-Hartman M., Deininger P.L. A consensus Alu repeat probe for physical mapping. Genet. Anal. Tech. Appl. 1994, 11:34-38.
48. Nicklas J.A., Buel E. Development of an Alu-based, real-time PCR method for quantitation of human DNA in forensic samples. J. Forensic Sci. 2003, 48:936-944.
49. Bijl M., Horst G., Limburg P.C., Kallenberg C.G. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2001, 60:523-526.
50. Dolff S., Wilde B., Patschan S., Durig J., Specker C., Philipp T., et al. Peripheral circulating activated B-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus. Scand. J. Immunol. 2007, 66:584-590.
51. Umetani N., Hiramatsu S., Hoon D.S. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann. N. Y. Acad. Sci. 2006, 1075:299-307.
52. Walker J.A., Kilroy G.E., Xing J., Shewale J., Sinha S.K., Batzer M.A. Human DNA quantitation using Alu element-based polymerase chain reaction. Anal. Biochem. 2003, 315:122-128.
53. Bernasconi N.L., Onai N., Lanzavecchia A. A role for toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003, 101:4500-4504.
54. Odendahl M., Jacobi A., Hansen A., Feist E., Hiepe F., Burmester G.R., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 2000, 165:5970-5979.
55. Papadimitraki E.D., Choulaki C., Koutala E., Bertsias G., Tsatsanis C., Gergianaki I., et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum. 2006, 54:3601-3611.
56. Migita K., Miyashita T., Maeda Y., Nakamura M., Yatsuhashi H., Kimura H., et al. Toll-like receptor expression in lupus peripheral blood mononuclear cells. J. Rheumatol. 2007, 34:493-500.
57. Nakano S., Morimoto S., Suzuki J., Nozawa K., Amano H., Tokano Y., et al. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 2008, 47:145-149.
58. Batzer M.A., Deininger P.L. Alu repeats and human genomic diversity. Nat. Rev. Genet. 2002, 3:370-379.
59. Munoz L.E., Janko C., Schulze C., Schorn C., Sarter K., Schett G., et al. Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE. Autoimmun. Rev. 2010, 10:38-42.
60. van der Vaart M., Pretorius P.J. Circulating DNA Its origin and fluctuation. Ann. N. Y. Acad. Sci. 2008, 1137:18-26.
61. Jiang N., Pisetsky D.S. The effect of dexamethasone on the generation of plasma DNA from dead and dying cells. Am. J. Pathol. 2004, 164:1751-1759.
62. Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 2011, 3:ra20-73.
63. Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 2011, 3:ra19-73.
64. Hakkim A., Furnrohr B.G., Amann K., Laube B., Abed U.A., Brinkmann V., et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. USA 2010, 107:9813-9818.
65. Remijsen Q., Vanden Berghe T., Wirawan E., Asselbergh B., Parthoens E., De Rycke R., et al. Neutrophil extracellular trap cell death requires both autophagy and superoxide generation. Cell Res. 2011, 21:290-304.
66. Barth S., Glick D., Macleod K.F. Autophagy: assays and artifacts. J. Pathol. 2010, 221:117-124.
67. Sharif M.N., Tassiulas I., Hu Y., Mecklenbrauker I., Tarakhovsky A., Ivashkiv L.B. IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J. Immunol. 2004, 172:6476-6481.
68. Grondal G., Gunnarsson I., Ronnelid J., Rogberg S., Klareskog L., Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol. 2000, 18:565-570.
69. Guiducci C., Gong M., Xu Z., Gill M., Chaussabel D., Meeker T., et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010, 465:937-941.
70. Cheema G.S., Roschke V., Hilbert D.M., Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001, 44:1313-1319.
71. Li X., Su K., Ji C., Szalai A.J., Wu J., Zhang Y., et al. Immune opsonins modulate BLyS/BAFF release in a receptor-specific fashion. J. Immunol. 2008, 181:1012-1018.
72. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002, 168:4531-4537.
73. Eilertsen G.O., Van Ghelue M., Strand H., Nossent J.C. Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study. Rheumatology 2011, 50:2197-2205.
74. Ritterhouse L.L., Crowe S.R., Niewold T.B., Merrill J.T., Roberts V.C., Dedeke A.B., et al. B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis Rheum. 2011, 63:3931-3941.
75. Hayashi F., Means T.K., Luster A.D. Toll-like receptors stimulate human neutrophil function. Blood 2003, 102:2660-2669.